Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Combination With Other Anti-Cancer Therapies in Advanced Malignancies
NCT03217747Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2017
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in malignant solid neoplasm, prostate carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2017; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
malignant solid neoplasmprostate carcinoma
Beyond the preview
Go deeper on NCT03217747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217747.